| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 102 | 2024 | 5097 | 6.330 |
Why?
|
| Pregnancy Complications, Infectious | 21 | 2023 | 529 | 4.500 |
Why?
|
| Viral Load | 28 | 2022 | 819 | 2.760 |
Why?
|
| HIV-1 | 31 | 2023 | 1260 | 2.640 |
Why?
|
| Anti-HIV Agents | 23 | 2022 | 1324 | 2.530 |
Why?
|
| Young Adult | 60 | 2025 | 2498 | 2.470 |
Why?
|
| South Africa | 108 | 2025 | 7596 | 2.460 |
Why?
|
| Adult | 89 | 2025 | 5913 | 2.290 |
Why?
|
| Adolescent | 67 | 2025 | 2985 | 2.220 |
Why?
|
| Cross-Sectional Studies | 39 | 2023 | 1422 | 2.140 |
Why?
|
| Humans | 136 | 2025 | 14537 | 2.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 17 | 2023 | 472 | 1.960 |
Why?
|
| Female | 92 | 2025 | 9103 | 1.950 |
Why?
|
| Prenatal Care | 8 | 2022 | 147 | 1.880 |
Why?
|
| Middle Aged | 48 | 2025 | 3601 | 1.700 |
Why?
|
| Pregnancy | 31 | 2023 | 1862 | 1.690 |
Why?
|
| AIDS Serodiagnosis | 8 | 2019 | 44 | 1.570 |
Why?
|
| Circumcision, Male | 17 | 2020 | 99 | 1.460 |
Why?
|
| Male | 77 | 2025 | 6754 | 1.440 |
Why?
|
| HIV | 14 | 2021 | 380 | 1.270 |
Why?
|
| Surveys and Questionnaires | 15 | 2022 | 563 | 1.150 |
Why?
|
| HIV Seropositivity | 9 | 2023 | 265 | 1.150 |
Why?
|
| Hepacivirus | 6 | 2020 | 37 | 1.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2020 | 262 | 1.080 |
Why?
|
| Prevalence | 30 | 2022 | 1192 | 1.050 |
Why?
|
| Syphilis | 2 | 2023 | 14 | 1.030 |
Why?
|
| Population Surveillance | 12 | 2019 | 325 | 0.970 |
Why?
|
| Pregnancy, Unplanned | 2 | 2022 | 19 | 0.960 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2022 | 103 | 0.960 |
Why?
|
| Condoms | 6 | 2022 | 88 | 0.940 |
Why?
|
| Genotype | 17 | 2020 | 442 | 0.920 |
Why?
|
| RNA, Viral | 11 | 2019 | 303 | 0.860 |
Why?
|
| Blood Donors | 4 | 2023 | 19 | 0.850 |
Why?
|
| Continuity of Patient Care | 4 | 2019 | 33 | 0.840 |
Why?
|
| Homosexuality, Male | 5 | 2021 | 52 | 0.830 |
Why?
|
| Ulcer | 4 | 2010 | 7 | 0.790 |
Why?
|
| Anti-Retroviral Agents | 10 | 2023 | 551 | 0.780 |
Why?
|
| Algorithms | 4 | 2017 | 106 | 0.780 |
Why?
|
| Herpes Genitalis | 8 | 2011 | 43 | 0.770 |
Why?
|
| Pregnant Women | 4 | 2023 | 89 | 0.750 |
Why?
|
| Drug Resistance, Viral | 9 | 2020 | 278 | 0.740 |
Why?
|
| Blood | 3 | 2016 | 51 | 0.730 |
Why?
|
| Sexual Behavior | 14 | 2020 | 320 | 0.720 |
Why?
|
| Hepatitis C | 3 | 2020 | 37 | 0.720 |
Why?
|
| Specimen Handling | 3 | 2012 | 105 | 0.720 |
Why?
|
| Sustained Virologic Response | 2 | 2017 | 22 | 0.680 |
Why?
|
| Genetic Variation | 5 | 2021 | 175 | 0.590 |
Why?
|
| Incidence | 17 | 2022 | 685 | 0.590 |
Why?
|
| Sex Workers | 5 | 2022 | 116 | 0.570 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 18 | 0.570 |
Why?
|
| Health Services Research | 2 | 2017 | 58 | 0.570 |
Why?
|
| Sensitivity and Specificity | 6 | 2023 | 385 | 0.560 |
Why?
|
| Interleukin-1 | 7 | 1999 | 12 | 0.540 |
Why?
|
| Mass Screening | 6 | 2020 | 245 | 0.510 |
Why?
|
| HLA-C Antigens | 2 | 2013 | 15 | 0.480 |
Why?
|
| CD4 Lymphocyte Count | 14 | 2021 | 656 | 0.470 |
Why?
|
| Family Characteristics | 5 | 2018 | 135 | 0.460 |
Why?
|
| Alleles | 6 | 2021 | 143 | 0.460 |
Why?
|
| Disease Outbreaks | 5 | 2013 | 111 | 0.450 |
Why?
|
| Haplotypes | 4 | 2021 | 125 | 0.450 |
Why?
|
| Infant | 19 | 2022 | 2244 | 0.440 |
Why?
|
| Sexual Partners | 6 | 2021 | 215 | 0.430 |
Why?
|
| Polymerase Chain Reaction | 9 | 2017 | 260 | 0.430 |
Why?
|
| Self Report | 5 | 2021 | 114 | 0.420 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2019 | 16 | 0.420 |
Why?
|
| Genital Diseases, Male | 2 | 2010 | 8 | 0.410 |
Why?
|
| Interleukin-18 | 5 | 2000 | 6 | 0.410 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2020 | 472 | 0.400 |
Why?
|
| Epidemics | 4 | 2022 | 65 | 0.400 |
Why?
|
| HLA-A Antigens | 1 | 2011 | 7 | 0.380 |
Why?
|
| HLA-B Antigens | 1 | 2011 | 12 | 0.380 |
Why?
|
| HLA-DRB1 Chains | 1 | 2011 | 17 | 0.380 |
Why?
|
| Herpesvirus 2, Human | 7 | 2011 | 43 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 256 | 0.370 |
Why?
|
| Interleukin-8 | 3 | 2021 | 21 | 0.370 |
Why?
|
| Aged | 9 | 2025 | 1740 | 0.370 |
Why?
|
| Alcohol-Related Disorders | 1 | 2010 | 1 | 0.360 |
Why?
|
| Depressive Disorder | 1 | 2010 | 10 | 0.360 |
Why?
|
| Child Abuse | 1 | 2010 | 10 | 0.360 |
Why?
|
| Child | 11 | 2021 | 2242 | 0.350 |
Why?
|
| HIV Seroprevalence | 7 | 2020 | 15 | 0.350 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 60 | 0.350 |
Why?
|
| Genitalia, Male | 1 | 2010 | 9 | 0.350 |
Why?
|
| Breast Feeding | 4 | 2020 | 120 | 0.340 |
Why?
|
| Infant, Newborn | 11 | 2019 | 1479 | 0.340 |
Why?
|
| Logistic Models | 2 | 2021 | 254 | 0.330 |
Why?
|
| Interferon-gamma | 6 | 2003 | 39 | 0.330 |
Why?
|
| Measles | 3 | 2014 | 36 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2000 | 44 | 0.320 |
Why?
|
| HLA Antigens | 4 | 2017 | 50 | 0.320 |
Why?
|
| Gene Frequency | 5 | 2021 | 122 | 0.310 |
Why?
|
| Antibodies, Viral | 4 | 2025 | 284 | 0.310 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2022 | 187 | 0.310 |
Why?
|
| Quality Control | 2 | 2019 | 27 | 0.310 |
Why?
|
| AIDS Vaccines | 2 | 2021 | 152 | 0.300 |
Why?
|
| Rural Population | 5 | 2020 | 654 | 0.300 |
Why?
|
| Cohort Studies | 9 | 2021 | 967 | 0.290 |
Why?
|
| Mutation | 5 | 2020 | 306 | 0.290 |
Why?
|
| Child, Preschool | 10 | 2021 | 1748 | 0.290 |
Why?
|
| Laboratory Proficiency Testing | 2 | 2019 | 6 | 0.290 |
Why?
|
| Age Factors | 4 | 2021 | 370 | 0.280 |
Why?
|
| Cytokines | 5 | 2000 | 107 | 0.280 |
Why?
|
| Quality Assurance, Health Care | 2 | 2019 | 43 | 0.280 |
Why?
|
| Time Factors | 7 | 2020 | 507 | 0.280 |
Why?
|
| Treatment Outcome | 7 | 2021 | 889 | 0.260 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2022 | 30 | 0.260 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2019 | 56 | 0.260 |
Why?
|
| HIV Antibodies | 5 | 2020 | 247 | 0.250 |
Why?
|
| Virus Shedding | 3 | 2010 | 24 | 0.250 |
Why?
|
| Health Surveys | 6 | 2019 | 59 | 0.250 |
Why?
|
| Lipopolysaccharides | 6 | 2000 | 37 | 0.250 |
Why?
|
| Socioeconomic Factors | 5 | 2021 | 411 | 0.250 |
Why?
|
| Fetal Blood | 1 | 2005 | 27 | 0.250 |
Why?
|
| Amniotic Fluid | 1 | 2005 | 13 | 0.250 |
Why?
|
| Nevirapine | 4 | 2015 | 146 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 3 | 2017 | 21 | 0.240 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 90 | 0.240 |
Why?
|
| Papillomavirus Infections | 3 | 2011 | 74 | 0.240 |
Why?
|
| Health Behavior | 1 | 2005 | 79 | 0.240 |
Why?
|
| Measles Vaccine | 3 | 2013 | 34 | 0.230 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 239 | 0.230 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 91 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 101 | 0.230 |
Why?
|
| Biomarkers | 4 | 2022 | 327 | 0.220 |
Why?
|
| False Positive Reactions | 2 | 2017 | 17 | 0.220 |
Why?
|
| Mothers | 4 | 2019 | 195 | 0.220 |
Why?
|
| Health Facilities | 2 | 2021 | 40 | 0.220 |
Why?
|
| World Health Organization | 3 | 2019 | 137 | 0.210 |
Why?
|
| Coinfection | 3 | 2017 | 276 | 0.210 |
Why?
|
| Penicillin G Benzathine | 1 | 2023 | 1 | 0.210 |
Why?
|
| Genetics, Population | 2 | 2021 | 52 | 0.210 |
Why?
|
| National Health Programs | 3 | 2017 | 78 | 0.210 |
Why?
|
| Influenza, Human | 3 | 2012 | 374 | 0.210 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2020 | 11 | 0.200 |
Why?
|
| Blood Cells | 2 | 2000 | 4 | 0.200 |
Why?
|
| Vaccination | 3 | 2013 | 365 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 1 | 2025 | 303 | 0.200 |
Why?
|
| Urban Population | 2 | 2020 | 257 | 0.200 |
Why?
|
| Serologic Tests | 2 | 2019 | 26 | 0.200 |
Why?
|
| Health Promotion | 2 | 2017 | 109 | 0.190 |
Why?
|
| Risk Factors | 10 | 2020 | 1475 | 0.190 |
Why?
|
| DNA, Viral | 4 | 2012 | 165 | 0.190 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 52 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 26 | 0.190 |
Why?
|
| Unsafe Sex | 4 | 2019 | 46 | 0.190 |
Why?
|
| Public Health | 2 | 2022 | 124 | 0.190 |
Why?
|
| Polysorbates | 1 | 2021 | 10 | 0.180 |
Why?
|
| Squalene | 1 | 2021 | 10 | 0.180 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 23 | 0.180 |
Why?
|
| Syphilis, Congenital | 1 | 2021 | 13 | 0.180 |
Why?
|
| Molecular Epidemiology | 2 | 2016 | 47 | 0.180 |
Why?
|
| Odds Ratio | 1 | 2021 | 133 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 468 | 0.180 |
Why?
|
| Killer Cells, Natural | 2 | 2017 | 52 | 0.170 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 103 | 0.170 |
Why?
|
| Interviews as Topic | 1 | 2021 | 203 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2011 | 54 | 0.170 |
Why?
|
| Linkage Disequilibrium | 3 | 2021 | 40 | 0.170 |
Why?
|
| Gene Expression Regulation | 2 | 1999 | 40 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2020 | 17 | 0.170 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 11 | 0.170 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 39 | 0.170 |
Why?
|
| Self Care | 1 | 2019 | 14 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2019 | 34 | 0.160 |
Why?
|
| Virion | 1 | 2019 | 12 | 0.160 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2019 | 5 | 0.160 |
Why?
|
| Postpartum Period | 4 | 2022 | 85 | 0.160 |
Why?
|
| Vaginal Smears | 1 | 2019 | 34 | 0.160 |
Why?
|
| Heroin Dependence | 1 | 2019 | 8 | 0.160 |
Why?
|
| Lymphocytes | 1 | 1999 | 20 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 1998 | 51 | 0.160 |
Why?
|
| Cell Phone | 1 | 2019 | 34 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2009 | 15 | 0.160 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2019 | 151 | 0.160 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 435 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2020 | 125 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 71 | 0.160 |
Why?
|
| Genotyping Techniques | 2 | 2016 | 38 | 0.160 |
Why?
|
| Vagina | 1 | 2019 | 91 | 0.160 |
Why?
|
| Social Desirability | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hepatitis B, Chronic | 1 | 2019 | 45 | 0.150 |
Why?
|
| Hepatitis B virus | 1 | 2020 | 157 | 0.150 |
Why?
|
| Community Health Services | 1 | 2018 | 58 | 0.150 |
Why?
|
| Interferon Inducers | 1 | 1998 | 1 | 0.150 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 1998 | 10 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 4 | 2013 | 181 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 33 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 59 | 0.150 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2015 | 15 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 198 | 0.150 |
Why?
|
| False Negative Reactions | 1 | 2017 | 4 | 0.140 |
Why?
|
| Disease Eradication | 1 | 2017 | 11 | 0.140 |
Why?
|
| Sex Distribution | 3 | 2018 | 89 | 0.140 |
Why?
|
| Retrospective Studies | 3 | 2016 | 799 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 25 | 0.140 |
Why?
|
| Salmonella enterica | 1 | 2017 | 1 | 0.140 |
Why?
|
| Salmonella Infections | 1 | 2017 | 3 | 0.140 |
Why?
|
| Receptors, KIR | 1 | 2017 | 23 | 0.140 |
Why?
|
| Sequence Analysis, Protein | 2 | 2015 | 10 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2017 | 82 | 0.140 |
Why?
|
| Disease Susceptibility | 2 | 2014 | 46 | 0.130 |
Why?
|
| Molecular Sequence Data | 6 | 2015 | 263 | 0.130 |
Why?
|
| Viral Core Proteins | 1 | 2015 | 10 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2015 | 57 | 0.120 |
Why?
|
| Age Distribution | 5 | 2018 | 107 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 280 | 0.120 |
Why?
|
| Maternal Health Services | 1 | 2015 | 52 | 0.120 |
Why?
|
| Models, Biological | 3 | 2021 | 77 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2014 | 7 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2020 | 1160 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 150 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2019 | 118 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2004 | 8 | 0.110 |
Why?
|
| Phylogeny | 6 | 2016 | 231 | 0.110 |
Why?
|
| Paralysis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Poliovirus | 1 | 2013 | 2 | 0.110 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2013 | 2 | 0.110 |
Why?
|
| Poliomyelitis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 1 | 2013 | 25 | 0.110 |
Why?
|
| Pneumonia | 1 | 1995 | 131 | 0.110 |
Why?
|
| Antiviral Agents | 2 | 2015 | 111 | 0.110 |
Why?
|
| Cluster Analysis | 2 | 2010 | 65 | 0.110 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2013 | 5 | 0.100 |
Why?
|
| Immunodominant Epitopes | 1 | 2012 | 2 | 0.100 |
Why?
|
| Population Density | 1 | 2013 | 13 | 0.100 |
Why?
|
| Abortion, Spontaneous | 1 | 2013 | 15 | 0.100 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2012 | 23 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 217 | 0.100 |
Why?
|
| Behavior Therapy | 2 | 2018 | 11 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 77 | 0.100 |
Why?
|
| Safe Sex | 2 | 2019 | 68 | 0.100 |
Why?
|
| Viruses | 1 | 2012 | 47 | 0.100 |
Why?
|
| Computational Biology | 1 | 2012 | 44 | 0.100 |
Why?
|
| Risk-Taking | 4 | 2019 | 121 | 0.100 |
Why?
|
| Rural Health | 5 | 2016 | 118 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 2 | 2025 | 109 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 171 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2000 | 79 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 132 | 0.090 |
Why?
|
| Inverted Repeat Sequences | 1 | 2011 | 3 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2021 | 272 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2015 | 12 | 0.090 |
Why?
|
| Models, Theoretical | 3 | 2018 | 80 | 0.090 |
Why?
|
| Sexual and Gender Minorities | 2 | 2021 | 29 | 0.090 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 51 | 0.090 |
Why?
|
| Hepatitis C Antibodies | 2 | 2020 | 3 | 0.090 |
Why?
|
| Conserved Sequence | 2 | 2012 | 10 | 0.080 |
Why?
|
| Propylene Glycols | 1 | 2009 | 3 | 0.080 |
Why?
|
| Phosphates | 1 | 2009 | 10 | 0.080 |
Why?
|
| Glycerol | 1 | 2009 | 8 | 0.080 |
Why?
|
| Cellulose | 1 | 2009 | 21 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2009 | 16 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2020 | 48 | 0.080 |
Why?
|
| Acyclovir | 1 | 2009 | 11 | 0.080 |
Why?
|
| Dried Blood Spot Testing | 2 | 2020 | 24 | 0.080 |
Why?
|
| Papillomaviridae | 1 | 2010 | 34 | 0.080 |
Why?
|
| Therapeutic Irrigation | 1 | 2009 | 4 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 370 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 266 | 0.080 |
Why?
|
| Contraceptive Devices, Female | 1 | 2009 | 30 | 0.080 |
Why?
|
| Antibody Specificity | 1 | 2009 | 30 | 0.080 |
Why?
|
| Surgical Instruments | 1 | 2009 | 11 | 0.080 |
Why?
|
| Trichomonas Infections | 1 | 2008 | 5 | 0.080 |
Why?
|
| Chlamydia trachomatis | 1 | 2008 | 13 | 0.080 |
Why?
|
| Trichomonas vaginalis | 1 | 2008 | 5 | 0.080 |
Why?
|
| Kinetics | 2 | 1999 | 65 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2008 | 18 | 0.080 |
Why?
|
| Pandemics | 1 | 2011 | 296 | 0.080 |
Why?
|
| Interleukin-10 | 2 | 1998 | 9 | 0.080 |
Why?
|
| Gene Products, gag | 2 | 2005 | 11 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2018 | 42 | 0.070 |
Why?
|
| United Nations | 2 | 2018 | 12 | 0.070 |
Why?
|
| Program Evaluation | 3 | 2018 | 89 | 0.070 |
Why?
|
| Tuberculosis | 2 | 2004 | 543 | 0.070 |
Why?
|
| Monocytes | 2 | 2021 | 27 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2019 | 101 | 0.070 |
Why?
|
| Animals | 6 | 2008 | 1081 | 0.070 |
Why?
|
| Viral Proteins | 2 | 2004 | 30 | 0.070 |
Why?
|
| Hemophilia A | 1 | 2008 | 106 | 0.070 |
Why?
|
| Domestic Violence | 1 | 2006 | 8 | 0.070 |
Why?
|
| Base Sequence | 3 | 2015 | 149 | 0.070 |
Why?
|
| Viremia | 2 | 2022 | 66 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 24 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2011 | 244 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 7 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2004 | 195 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 1999 | 73 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 139 | 0.050 |
Why?
|
| Mice | 3 | 1999 | 135 | 0.050 |
Why?
|
| Epitopes | 1 | 2003 | 97 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2003 | 56 | 0.050 |
Why?
|
| Government | 1 | 2022 | 13 | 0.050 |
Why?
|
| Spleen | 2 | 1999 | 9 | 0.050 |
Why?
|
| In Vitro Techniques | 2 | 1999 | 54 | 0.050 |
Why?
|
| Reference Values | 2 | 1998 | 64 | 0.050 |
Why?
|
| Heterosexuality | 1 | 2002 | 30 | 0.050 |
Why?
|
| Canarypox virus | 1 | 2021 | 4 | 0.050 |
Why?
|
| Phytohemagglutinins | 1 | 2021 | 9 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 1999 | 32 | 0.050 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Sentinel Surveillance | 1 | 2002 | 115 | 0.050 |
Why?
|
| Employment | 1 | 2021 | 27 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2021 | 55 | 0.040 |
Why?
|
| Sex Work | 1 | 2021 | 39 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 2 | 1998 | 5 | 0.040 |
Why?
|
| Aspirin | 1 | 2000 | 15 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 72 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 51 | 0.040 |
Why?
|
| Apolipoprotein A-I | 1 | 2000 | 3 | 0.040 |
Why?
|
| fas Receptor | 1 | 2000 | 13 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2020 | 120 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2000 | 15 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2013 | 225 | 0.040 |
Why?
|
| Technology, Pharmaceutical | 1 | 2000 | 35 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 353 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2019 | 15 | 0.040 |
Why?
|
| Lactation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Glycogen | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2000 | 80 | 0.040 |
Why?
|
| Coitus | 1 | 2019 | 15 | 0.040 |
Why?
|
| Homeless Persons | 1 | 2019 | 1 | 0.040 |
Why?
|
| Needle Sharing | 1 | 2019 | 1 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 1 | 0.040 |
Why?
|
| Needle-Exchange Programs | 1 | 2019 | 3 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2019 | 7 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 14 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2004 | 480 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 64 | 0.040 |
Why?
|
| Drug Synergism | 1 | 1998 | 20 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2018 | 22 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1998 | 15 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 156 | 0.040 |
Why?
|
| Global Health | 1 | 2000 | 193 | 0.040 |
Why?
|
| Comprehension | 1 | 2018 | 5 | 0.040 |
Why?
|
| Bias | 1 | 2018 | 15 | 0.040 |
Why?
|
| South America | 2 | 2011 | 27 | 0.040 |
Why?
|
| Vaccines | 1 | 2000 | 86 | 0.040 |
Why?
|
| Developing Countries | 2 | 2015 | 400 | 0.040 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2008 | 41 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 4 | 0.040 |
Why?
|
| Goals | 1 | 2018 | 7 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 1998 | 2 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1998 | 5 | 0.040 |
Why?
|
| CD3 Complex | 1 | 1998 | 14 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 65 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 1998 | 49 | 0.040 |
Why?
|
| Health Policy | 1 | 2019 | 140 | 0.040 |
Why?
|
| Epitope Mapping | 2 | 2009 | 32 | 0.040 |
Why?
|
| India | 1 | 2017 | 62 | 0.040 |
Why?
|
| Women | 1 | 2017 | 12 | 0.030 |
Why?
|
| Salmonella typhimurium | 1 | 2017 | 4 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 143 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 40 | 0.030 |
Why?
|
| Perception | 1 | 2017 | 42 | 0.030 |
Why?
|
| Motivational Interviewing | 1 | 2017 | 10 | 0.030 |
Why?
|
| Suburban Population | 1 | 2016 | 9 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 99 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 176 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 321 | 0.030 |
Why?
|
| Educational Status | 2 | 2006 | 68 | 0.030 |
Why?
|
| Interferons | 1 | 2015 | 9 | 0.030 |
Why?
|
| Ribavirin | 1 | 2015 | 15 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 227 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 167 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 48 | 0.030 |
Why?
|
| Home Childbirth | 1 | 2015 | 5 | 0.030 |
Why?
|
| Maternal Age | 1 | 2015 | 22 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2015 | 18 | 0.030 |
Why?
|
| Parity | 1 | 2015 | 19 | 0.030 |
Why?
|
| APACHE | 1 | 1995 | 12 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 2015 | 15 | 0.030 |
Why?
|
| Zidovudine | 1 | 2015 | 59 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 279 | 0.030 |
Why?
|
| Measles virus | 1 | 2014 | 6 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 124 | 0.030 |
Why?
|
| Critical Illness | 1 | 1995 | 44 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1995 | 54 | 0.030 |
Why?
|
| Africa, Southern | 2 | 2005 | 91 | 0.030 |
Why?
|
| Malawi | 1 | 2014 | 87 | 0.030 |
Why?
|
| Disease Progression | 2 | 2005 | 154 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 1995 | 102 | 0.030 |
Why?
|
| Muscle Hypotonia | 1 | 2013 | 1 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2013 | 8 | 0.030 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2013 | 6 | 0.030 |
Why?
|
| Democratic Republic of the Congo | 1 | 2013 | 10 | 0.030 |
Why?
|
| Feces | 1 | 2013 | 30 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 9 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 105 | 0.030 |
Why?
|
| Immunoassay | 1 | 2013 | 28 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2013 | 16 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2013 | 24 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 18 | 0.030 |
Why?
|
| Databases, Protein | 1 | 2012 | 2 | 0.030 |
Why?
|
| Oropharynx | 1 | 2012 | 17 | 0.030 |
Why?
|
| Spatial Analysis | 1 | 2013 | 10 | 0.030 |
Why?
|
| Humidity | 1 | 2012 | 5 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2013 | 81 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 1992 | 43 | 0.030 |
Why?
|
| Desiccation | 1 | 2012 | 15 | 0.030 |
Why?
|
| Temperature | 1 | 2012 | 56 | 0.020 |
Why?
|
| Scleritis | 1 | 1992 | 1 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 188 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 198 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2012 | 151 | 0.020 |
Why?
|
| Australasia | 1 | 2011 | 2 | 0.020 |
Why?
|
| Human papillomavirus 11 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Human papillomavirus 6 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 59 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 376 | 0.020 |
Why?
|
| Cote d'Ivoire | 1 | 2010 | 6 | 0.020 |
Why?
|
| Arthropods | 1 | 1990 | 1 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 45 | 0.020 |
Why?
|
| Kenya | 1 | 2010 | 183 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2009 | 21 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 5 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 38 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1989 | 9 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 418 | 0.020 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 43 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 22 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2009 | 44 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 15 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 56 | 0.020 |
Why?
|
| Urethra | 1 | 2009 | 2 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2009 | 120 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 83 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2009 | 108 | 0.020 |
Why?
|
| Gonorrhea | 1 | 2009 | 20 | 0.020 |
Why?
|
| Sex Education | 1 | 2008 | 17 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 221 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 158 | 0.020 |
Why?
|
| HIV Protease | 1 | 2008 | 22 | 0.020 |
Why?
|
| Sequence Homology | 1 | 2007 | 11 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2007 | 31 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 35 | 0.020 |
Why?
|
| Family | 1 | 2006 | 35 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 48 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 31 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 188 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2004 | 6 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 22 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 20 | 0.010 |
Why?
|
| HIV Antigens | 1 | 2004 | 26 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 26 | 0.010 |
Why?
|
| Cell Division | 2 | 1998 | 12 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 62 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 37 | 0.010 |
Why?
|
| Poverty | 1 | 2005 | 152 | 0.010 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 54 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 27 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 55 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 127 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 127 | 0.010 |
Why?
|
| Survival Rate | 1 | 2000 | 96 | 0.010 |
Why?
|
| Echocardiography | 1 | 2000 | 100 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 199 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1998 | 2 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1998 | 64 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 125 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1998 | 1 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Zymosan | 1 | 1998 | 2 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 1998 | 2 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 1998 | 2 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1998 | 5 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1998 | 13 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 40 | 0.010 |
Why?
|
| Immunization | 1 | 1998 | 63 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 2 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 11 | 0.010 |
Why?
|
| Papio | 1 | 1992 | 28 | 0.010 |
Why?
|
| Species Specificity | 1 | 1992 | 49 | 0.010 |
Why?
|
| Biological Assay | 1 | 1992 | 32 | 0.010 |
Why?
|
| Hemolymph | 1 | 1990 | 1 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1990 | 30 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1990 | 61 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1989 | 2 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1989 | 7 | 0.010 |
Why?
|
| Cell Count | 1 | 1989 | 10 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1989 | 22 | 0.010 |
Why?
|
| Binding Sites | 1 | 1989 | 43 | 0.010 |
Why?
|
| Cell Line | 1 | 1989 | 93 | 0.010 |
Why?
|